Addition marks milestone for Company as the LatAm
integrated medical cannabis market leader
TORONTO, Dec. 31, 2018 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN),
(OTCQB: KHRNF), (Frankfurt:
A2JMZC), an integrated medical cannabis company with its core
operations in Colombia, announced
today that the Company has been added to the Horizons Marijuana
Life Sciences Index ETF ("HMMJ:TSX"), marking the Company's
elevation to the senior index of publicly traded North American
companies with significant business activity in the cannabis
industry.
HMMJ is an index (or passively managed) ETF, which seeks to
replicate, to the extent possible, the performance of the North
American Marijuana Index, net of expenses. This index is designed
to provide exposure to the performance of a basket of North
American publicly listed life sciences companies with significant
business activities in the Marijuana industry. The North American
Marijuana Index selects from a current universe of companies that
have operations that may include one or more of biopharmaceuticals,
medical manufacturing, distribution, bio-products and other
ancillary businesses related to the Marijuana industry.
The ETF's full holdings can be viewed directly at the link
below:
https://www.horizonsetfs.com/hmmj
About Khiron
Khiron Life Sciences Corp. is positioned to be the
dominant integrated medical cannabis company in Latin America. Khiron has core operations in
Colombia and is fully licensed in
the country for the cultivation, production, domestic distribution,
and international export of both THC (tetrahydrocannabinol) and CBD
(cannabidiol)medical cannabis. In May
2018, Khiron listed on the TSX Venture Exchange, becoming
one of the first Colombian based medical cannabis companies to
trade on any exchange globally.
With a focused regional strategy and patient oriented
approach, the Company combines global scientific expertise,
agricultural advantages, branded product market entrance
experience and education to drive prescription and brand
loyalty to address priority medical conditions such as chronic
pain, epilepsy, depression and anxiety in the Latin American
market of over 620 million people. Khiron is led by Co-founder and
Chief Executive Officer, Alvaro
Torres, together with an experienced executive team,
and a knowledgeable Board of Directors that includes former
President of Mexico, Vicente Fox.
Further information on Khiron Life Sciences can be found
at https://investors.khiron.ca/
Cautionary Notes
Market and Industry Data
This press release contains market and industry data and
forecasts that were obtained from third-party sources, industry
publications and publicly available information. Third-party
sources generally state that the information contained therein has
been obtained from sources believed to be reliable, but there can
be no assurance as to the accuracy or completeness of included
information. Although management believes it to be reliable, the
Company has not independently verified any of the data from
third-party sources referred to in this press release, or analyzed
or verified the underlying studies or surveys relied upon or
referred to by such sources, or ascertained the underlying economic
assumptions relied upon by such sources.
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable Canadian securities legislation. All information
contained herein that is not historical in nature may constitute
forward-looking information. Forward-looking statements may be
identified by statements containing the words "believes",
"anticipates", "plans", "intends", "will", "should", "expects",
"continue", "estimate", "forecasts" and other similar expressions.
Forward-looking statements herein include, but are not limited to,
statements regarding the final acceptance of the TSXV and the
commencement of sales in Mexico.
Readers are cautioned to not place undue reliance on
forward-looking information. Actual results and developments may
differ materially from those contemplated by these statements.
Khiron undertakes no obligation to comment analyses, expectations
or statements made by third-parties in respect of Khiron, its
securities, or financial or operating results (as applicable).
Although Khiron believes that the expectations reflected in
forward-looking statements in this press release are reasonable,
such forward-looking statement has been based on expectations,
factors and assumptions concerning future events which may prove to
be inaccurate and are subject to numerous risks and uncertainties,
certain of which are beyond Khiron's control, including the risk
factors discussed in Khiron's Annual Information Form which is
available on Khiron's SEDAR profile at www.sedar.com. The
forward-looking information contained in this press release is
expressly qualified by this cautionary statement and are made as of
the date hereof. Khiron disclaims any intention and has no
obligation or responsibility, except as required by law, to update
or revise any forward-looking information, whether as a result of
new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
SOURCE Khiron Life Sciences Corp.